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Abstract: Frailty is the major expression of accelerated aging and describes a decreased resistance
to stressors, and consequently an increased vulnerability to additional diseases in elderly people.
The vascular aging related to frail phenotype reflects the high susceptibility for cardiovascular
diseases and negative postoperative outcomes after cardiac surgery. Sarcopenia can be considered
a biological substrate of physical frailty. Malnutrition and physical inactivity play a key role in the
pathogenesis of sarcopenia. We searched on Medline (PubMed) and Scopus for relevant literature
published over the last 10 years and analyzed the strong correlation between frailty, sarcopenia and
cardiovascular diseases in elderly patient. In our opinion, a right food intake and moderate intensity
resistance exercise are mandatory in order to better prepare patients undergoing cardiac operation.
Keywords: frailty; vascular aging; age related syndrome; sarcopenia; malnutrition
1. Introduction
The concept of frailty was first evidenced in the 1979 [1] and entered in the common
medical language, thanks to recognized value in predicting the risk to many chronic dis-
eases in old population, evidencing the marked differences in the two sexes (especially in
female people), with respect to the traditional risk factors for these diseases, and in facili-
tating (or precisely quantifying) the increase of health age-related deficits. Nevertheless,
its definition remains uncertain, although three researchers have advanced some major pro-
posals: (1) Fried [2] defines frailty as the process that decreases the physiological reserves
and results in a major vulnerability to stressors (pathologies, surgery); (2) Rockwood [3] de-
scribes it as the result of the presence of adverse variables in old people, including those of
cardiovascular nature (i.e., hypertension, heart attack and arrhythmia); (3) Gobbens [4] sug-
gests that damages in the psychosocial sphere of an individual cause some adverse effects
to the health. Currently, advances in the field propose frailty as major phenotype of accel-
erated aging characterized by a multiorgan dysfunction and/or significantly associated
with an increased vulnerability to diverse diseases (multimorbidity) in elderly people [5].
Sarcopenia can be considered a biological substrate of physical frailty [6]. Muscle loss
typically begins in the fifth decade of life and proceeds at a rate of decline of 0.8% years [7].
Epidemiological data suggest a wide variability in the prevalence of sarcopenia, depending
on the type of population studied, sex, age and diagnostic criteria used. The prevalence
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of sarcopenia is between 7.5% and 77.6% [8]. There are numerous factors responsible for
this muscle loss: the aging process, genetic susceptibility, environmental factors, such as
suboptimal diet, prolonged bed rest, sedentary lifestyle, chronic diseases and drugs [9,10].
In most cases the etiology of sarcopenia is multifactorial and sarcopenia is considered PRI-
MARY (age-related) when the only obvious cause is aging [11–14]. Malnutrition plays a key
role in the pathogenesis of sarcopenia and frailty. The malnutrition refers to an imbalance
condition of protein or other nutrient imbalance, responsible for negative effects on body
composition, physical function and clinical outcome [15]. Although, malnutrition is not in-
evitably associated with the aging process. Numerous causes can contribute to a decline in
nutritional status: anorexia, edentulism, dysgeusia, dysphagia, motor and visual disability
represent physiological and physical causes that can compromise an adequate intake of nu-
trients [16]. We will see in this narrative review the correlation between frailty, sarcopenia
and malnutrition in the management of the elderly patient. At the same time, we proposed
a right food intake in order to better prepare patients undergoing cardiac surgery.
2. Materials and Methods
2.1. Data Sources and Search Strategy
Current literature investigating frailty, sarcopenia and malnutrition is analyzed and
contextualized in this review. Specifically, research was conducted on Medline (Pubmed)
and Scopus. To review recent studies on frailty, sarcopenia, malnutrition, and cardiovascu-
lar disease, we selected scientific papers published in English 10 years since the European
Working Group on Sarcopenia in Older People (EWGSOP) was published in 2010 [17].
We used the search term frailty, sarcopenia, malnutrition, cachexia, cardiovascular disease,
mortality and morbidity, cardiac surgery.
2.2. Study Selection
2.2.1. Inclusion Criteria
The inclusion criteria for the included studies in this review were as follows: (1) as-
sessment of frailty and sarcopenic patients; (2) inclusion of both gender and all races;
(3) examination of the impact of undernutrition, sarcopenia and frailty on clinical outcomes;
(4) frailty evaluation; (5) evaluation of muscle strength and/or muscle mass for diagnosing
sarcopenia; (6) evaluation of the correlation between frailty/sarcopenia and cardiovas-
cular diseases; (7) identification of frailty biomarkers in predicting vascular aging and
cardiovascular disease; (8) morbidity and mortality in frailty patients underwent cardiac
surgery; (9) application of a specific dietary intake in order to prevent sarcopenia in cardiac
surgery patients.
2.2.2. Exclusion Criteria
Editorial, case report, letters to editor, and conference abstracts were excluded from
this review.
3. Frailty Definition and Quantification
Two main models have been proposed for the frailty evaluation: the phenotypic (pri-
mary frailty) or the deficits accumulation model (secondary frailty). Different instruments
have been proposed for measuring frailty. Of note are the data from the Cardiovascular
Health Study [18] that evidenced in about 25% of older participants signs of frailty with-
out either multiple comorbidities or disabilities (physiological ageing). In this context,
frailty has been defined as “primary frailty”, with a phenotypic presentation involving
the decline in physical functions and psychological status, without taking into considera-
tion associated diseases or pathological conditions. In measuring the primary frailty, the
Fried’s phenotype frailty index has been widely adopted [2]. It derived from an analysis
of five health factors: nutrition; physical exhaustion; low energy expenditure (or inactive
status); mobility and muscular strength. Deterioration in one of these examined factors
was scored as 1 if present or 0 if absent, giving a potential score spanning from 0 to 5.
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The phenotypic model permitted to classify three groups of individuals: robust (no de-
terioration); pre-frail (one or two altered factors); or frail (three or more altered factors).
This classification was independently correlated with outcomes, such as survival, falls,
disability, and institutionalization. The secondary frailty considered the accumulation of
multiple deficits, including symptoms, signs, disabilities, pathological conditions, and
abnormal laboratory values. Furthermore, its evaluation was based on frailty index based
on the defects accumulation’s model [19]. Every deficit has been coded as binary (1 or 0)
or ordinal (0, 0.5, 1), consequently the frailty index was the sum of the deficit’s values
divided by the total number of deficits listed. This approach evidenced an important issue
on measurement of frailty based on phenotypic or deficits accumulation model, that has
revealed it is complex and time consuming. Alternative and easier instruments have
been, subsequently, proposed for fragility assessment both in general population or in
clinical practice [20]. For frailty estimation in general population, two simple scales and
multifaceted tools requiring comprehensive geriatric assessment (CGA) have been intro-
duced. Among the scales, the most important tool adopted is the Edmonton frailty scale
(EFS) [21]. It examines nine domains of frailty (cognition, general health status, functional
independence, social support, medication usage, nutrition, mood, continence, functional
performance). The results have been reported in a scale ranging from 0 to 17 values and
the participants have been conventionally classified into three categories. A higher score
has been associated with a higher degree of frailty. The same nine domains of frailty have
been also assessed by using a specific tool requiring comprehensive geriatric assessment.
For example, this is the case of the Mini-Mental State Examination (MMSE) [22] or the
Geriatric Depression Scale (GDS) [23,24]. In contrast, the functional performance has been
detected by using the Handgrip strength test [25,26]: handgrip measurement is assessed
on the dominant hand using a Jamar dynamometer adhering to the standardized protocol
recommended by the American Society of Hand Therapists and the average value of the
handgrip in the two genders is used to define the scores. Thus, a lower score than 30 kg
for man and lower than 20 kg for women is considered weak [27]. The valuation of the
nutritional status has been performed using the Mini Nutritional Assessment (MNA) [28].
The MNA is composed of 18 items divided in four categories: anthropometric assessment,
general state, dietary assessment, and self-assessment. A score ≥24 points indicates a good
nutritional status. A score from 17 to 23.5 points is an indicator of a risk of malnutrition,
while a score ≤17 points indicates malnutrition. In the appraisal of the general health
status, the assessment of the sarcopenia [29], osteoporosis [30], and serum albumin [31] is
important. Beside the instruments used to estimate fragility in general population, it is nec-
essary to mention the main tests used in hospital environment. Among these the SHARE-FI
scale [32] (Survey on Health, Ageing and Retirement in Europe Frailty Instrument) is one
of the most counted. This instrument is based on the first wave of the Survey of Health,
Ageing and Retirement in Europe, a large population-based survey (n = 31,115) conducted
in 2004–2005 in 12 European countries. It measures five variables approximating Fried’s
frailty definition (exhaustion, weight loss, weakness, slowness, and low activity) with
different coefficients for men and women. Another important scale is the SPPB [33] (Short
Physical Performance Battery). This battery analyzes physical performance features as
4-m gait speed, balance capacity and sit-to-stand time. The lower extremity performance
is a long-term mortality predictor independent of NYHA class and ejection fraction in
elderly hospitalized patients. The EFT [34] (Essential Frailty Instrument) is a specific scale
used in cardiac surgery. This scale includes biological, physical and mental state thus it
may identify subclinical frailty; in fact, its features are albumin and hemoglobin blood
values, sit-to-stand time and MMSE test. In the context of cardiac surgery two important
risk scores have been introduced in order to predict 30-day mortality and 1-year mortality:
respectively, the Comprehensive assessment of frailty [35] (CAF) and the Frailty predicts
death One years after Elective Cardiac Surgery Test (FORECAST) [36]. The CAF is com-
posed of different items to quantify the physical performance and coordinative abilities
of the patients in addition to scores that are already used to define frailty in medicine.
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In addition, several laboratory tests result as creatinine and FEV1. The FORECAST is a
simple version of the CAF with a higher predictive power. It is composed of those five test
items (chair rise, weak, stair, clinical frailty scale from the Canadian Study of Health and
Aging, serum creatinine level).
4. Sarcopenia as Biological Substrate of Physical Frailty
Sarcopenia is considered the biological substrate of physical frailty. The prevalence
of sarcopenia is higher in male with low body max index (BMI) [37,38]. Sarcopenia is
a common condition in the elderly but can also be seen in younger patients. It is de-
fined primary or age related when no cause is highlighted, other than the aging process.
It is considered secondary when one or more causes are identifiable and in this case it is
called activity-related, disease-related, nutrition-related [39]. Sarcopenia is a syndrome
characterized by the progressive and generalized loss of mass, muscle strength, physi-
cal performance, which leads to an increased risk of disability, poor quality of life, falls,
numerous complications, and death [40]. Muscle trophism is a consequence of a balance
between anabolic triggers (insulin, physical exercise, amino acids, adrenaline, testosterone)
and catabolic triggers (cortisol, catecholamines, glucagon, cytokines, intense exercise) [41].
In the elderly, the catabolic state is associated with the normal aging process, which be-
comes predominant when particular conditions of comorbidity are concomitant. In these
cases, the muscle mass suffers the effects of the general catabolic state in which the body is
found. Several factors contribute to the pathophysiology of sarcopenia [42]. In particular
the main factor are reduction of sex hormone levels, reduction of growth hormone levels,
increased production of cytokines, interleukin-1 (IL-1), interleukin-6 (IL-6), Tumor Necrosis
Factor-Alpha (TNF-alpha), alteration of the cellular redox-status, neuromuscular changes,
physical inactivity, and malnutrition [43,44]. Drugs can also play a protective or causative
role in the development of sarcopenia. Statins, sulfonylureas, glinides have a potential
harmful effect on muscle metabolism; while ACE inhibitors, allopurinol, Vitamin D play
a protective role on muscle function [45,46]. The muscle is formed of different types of
muscle fibers: slow fibers (type I) and fast fibers (types IIa and IIb). With aging, especially
in sarcopenic patients, there is a reduction in the diameter of muscle fibers, as well as a
progressive loss of fast fibers which results in a reduction in strength, coordination of move-
ments, and walking speed. This happens because the lost fast muscle fibers are replaced by
slow fibers. Given the dynamic nature of neuromuscular remodeling, it has been seen that
the muscle of the elderly subject under certain triggers maintains the ability to respond and
to adapt to the new state. It has been shown that even lifestyle alone can greatly influence
the development of muscle mass. This means that effective therapeutic intervention could
be applied in order to reverse the processes that lead to sarcopenia [47,48].
5. Sarcopenia Diagnosis
The simultaneous presence of muscle mass loss associated with reduced muscle
strength or physical performance is recommended for the diagnosis of sarcopenia. There are
various methods for the assessment of the sarcopenia.
The muscle mass usually is calculated using the Impedancemetry [49]. This is a valid
and recognized alternative to more complex and expensive methods, such as magnetic
resonance imaging (MRI), dual X-ray absorptiometry (DEXA) and computed tomography
(CT). The exam lasts a few minutes, is absolutely painless, safe and allows you to know
the body areas in terms of fat, lean tissue and water content. It is based on the principle
that tissues full of water and electrolytes offer less resistance to the passage of an electric
current than adipose tissue. The result is then compared with the reference values obtained
according to normalization formulas for race, age, sex, body weight. Muscle strength is
measured through the Handgrip (dynamometer), a simple tool that evaluates the force
developed by gripping the hand; usually three tests are performed, of which the best is
chosen [50]. The result is compared with threshold values calculated according to age,
sex and BMI. Physical performance can be assessed through the quick and easy walking
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speed test [51]. The main symptoms related to sarcopenia are muscle weakness and fatigue.
This concept does not only concern the bedridden people but also the person who has
functional autonomy. This condition does not only concern the thin and undernourished
patient, but even obese patient with increased body max index that have a reduction in
muscle mass. This scenario is called sarcopenic obesity [52]. Sarcopenic obesity is related to
an increased cardiovascular risk, due to the unfavorable metabolic effects of the increased
visceral adipose component. The muscle tissue is one of the major contributors to the
peripheral action of insulin on the uptake of circulating glucose. The sarcopenic patient also
has a condition of insulin resistance which can contribute to establishing and maintaining
harmful metabolic circulation.
6. Role of Frailty and Sarcopenia in Cardiovascular Disease
Cardiovascular disease (CVD), both clinical and subclinical, has been proposed as one
of the pathological conditions associated with frailty [53]. The Women’s Health Initiative
Observational Study has been the first and largest study to confirm that CVD was a risk
factor for developing frailty [54]. The relationship between these conditions indicates a com-
mon pathophysiological mechanism characterized by an abnormal inflammatory response,
resulting in an increase in inflammatory markers, leading to chronic inflammation [55].
On the other hand, chronic inflammation is the main cause of endothelial dysfunction that
leads to onset of cardiovascular diseases. The association between endothelial dysfunction
and frailty confirms the role of CVD in frailty. This suggests its relevance since the early
stages of vascular dysfunction (in case of only functional impairment) are apparent [56].
The endothelial dysfunction has been associated with a lot of cardiovascular risk factors:
hypertension, hypercholesterolemia, diabetes mellitus, obesity, smoking. Ricci et al. [57] in
a population-based study assessed that frail and pre-frail older people corresponded to a
substantial proportion of those with greater CVD risk factor. In particular, diabetes mellitus
(DM) seems to be the most prevalent CVD risk factor in frail and pre-frail older people.
It has been demonstrated that DM is one of the strongest risk factors for atherosclerosis and,
consequently, diabetic individuals present an increased risk, 3–4 times higher, of develop-
ing CVD and a double risk of mortality when compared to general population. Cacciatore
et al. [58] in a 12-year survival analysis study, showed that frail individuals were 2.6 times
more likely to have a complication related to DM, regarding age, sex, and number of years
living with this pathology. The relationship between DM and frailty seems to be influenced
by the sarcopenia. The muscle impairment in diabetic people is the result of fat infiltration
in the muscle tissue, higher insulin resistance levels, the increased levels of cytokines, and
reduction in motor and plates. Other important CVD risk factors in older people are hyper-
tension and smoking, regardless of the frailty classification. No relationship has been found
between frailty, obesity and waist circumference. Anyway, the concept of sarcopenic obesity
behind the BMI has been introduced: frail people are characterized by sarcopenia and fat
infiltration of muscle. This increased fat tissue allows the production of proinflammatory
cytokines and mediators, such as interleukin-6 and C-reactive protein, which induces a
state of chronic inflammation present in the frailty syndrome [59]. Therefore, it is interest-
ing to note that aging per se induces endothelial dysfunction, in absence of cardiovascular
risk factor and CVD related to increased oxidative stress and proinflammatory profile [60].
7. Crosstalk between Frailty and Cardiovascular Diseases in Molecular
Mechanisms Level
Recent literature data suggest considering the pathophysiological mechanisms in-
volved in the development or progression of a frailty status, for identifying frailty biomark-
ers [61,62]. In the context of vascular aging related to frail phenotype, several mechanisms
are strongly associated with the onset of cardiovascular disease [63]. For example, inflam-
mation is the predominant mechanism in vascular aging that induces the activation of
endothelial and vascular smooth muscle cells and the migration in the wall of leukocytes.
They may evolve in atherosclerosis condition or in other degenerative pathological age-
related conditions. According a recent review, there are 44 most important biomarkers
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related to frailty. They propose a core panel of 19 high priority markers and an expanded
panel with 22 medium priority markers [64]. In addition, three low priority markers are
reported. These markers might be assembled in different groups according the mechanism
in which they are involved: inflammation, mitochondria and apoptosis, calcium homeosta-
sis, fibrosis, neuromuscular junction and neurons, cytoskeleton and hormones, and others.
Alterations in immune system seem to be one of the most important triggers related to vas-
cular aging. According Monti et al. [65], the aging process is related to a systemic increase
in proinflammatory mediators from various sources. In addition, aging induces important
changes in immune cell phenotypes and function, called “immunosenescence”. It is charac-
terized by a shift from lymphoid to myeloid differentiation was described for B and T cell
populations. Equally, there is a change in the function and receptor signaling (i.e., Toll-like
receptors and RAGE) in monocytes, macrophages, dentritic cells, and neutrophils. More-
over, immune cells go through “immunosenescence” process [66]. These cells change their
surface marker expression, reduce the production of reactive oxygen species (ROS) and their
migration capacity, increase the production of proinflammatory over anti-inflammatory
cytokines. All these events induce the release of inflammatory molecules that might be
used as vascular aging and fragility biomarkers. The most important inflammatory mark-
ers are CD14 antigen also known as myeloid cell-specific leucine rich glycoprotein [67];
CX3CL1 (C-X3-C motif chemokine ligand 1, aka fractalkine) [68,69]; pentraxin [70,71];
sVCAM (soluble vascular cell adhesion molecule 1/soluble intercellular adhesion molecule
1) [72,73]; IL-6 (interleukin 6) [74,75]; CXCL 10 (C-X-C motif chemokine 10) [76]; defensins
(a large family of antimicrobial and cytotoxic peptides involved in host defense and in im-
munomodulation) [77]. Among these seven potential inflammatory biomarkers for frailty,
three seem to have high priority (IL-6, CXCL10, CX3CL1), three medium priority (pen-
traxin, sVCAM/sICAM, defensin), and one low priority candidate (CD14) [64]. The other
group of frailty biomarkers is related to the impairment of mitochondrial function and
apoptosis typical of several ageing disorders [78]. Among these the most important are
GDF15 (growth differentiation factor 15 or myomitokine) [79]; FNDC5 (fibronectin type
III domain containing 5) [80]; Vimentin (type III intermediate filament protein) [81]; APP
(amyloid precursor protein beta) [82]; LDH (lactate dehydrogenase) [83]. From the five
markers in the mitochondria and apoptosis category, the profile of GDF15, FNDC5 and
vimentin are considered high priority biomarkers [64]. In addition, because in aged people
the calcium homeostasis is usually altered, changes in calcium signaling and/or binding
proteins have been proven to be effective markers of cellular and tissue dysfunction in
these patients. The three “calcium homeostasis” biomarkers of fragility are S100B (S 100
calcium binding protein B) [84]; SMP30 (senescence-marker protein 30) [85]; calreticulin (a
multifunctional protein initially identified as a Ca2+ storage protein) [86]. Both regucalcin
and calreticum reached high priority. Another important group of biomarkers is related
to fibrotic changes that various tissues show with age. One of the most important factors
involved in the fibrosis is the transforming growth factor-ß (TGF-ß) [87]. A higher concen-
tration of TGF-ß seems to be related to various diseases associated to age and fragility such
as atherosclerosis, acute and chronic liver and kidney disease, autoimmunity, osteoarthritis,
and neurodegenerative diseases [88]. Other fibrosis markers related to the TGF-ß pathway
activation are PAI-19 (plasminogen activator inhibitor1) [89]; PLAU (urokinase plasmino-
gen activator) [90]; MMP7 (matrix metalloproteinases 7) [91]; TGM2 (transglutaminase
2) [92]; THBS2 (thrombospondin 2) [93]; AGT100 (angiotensinogen) [94]. Yet, with the
aging syndrome there is a damage of the cell cytoskeleton that leads to hormones dysreg-
ulation [95]. Consequently, a lot of hormones could likely be used as frailty biomarkers,
such as the GH (growth hormone), IGF (insulin-like growth factor-1), FGF23 (fibroblast
growth factor 23), resistin, adiponectine, leptin, and ghrelin.
8. Clinical Impact of Frailty and Sarcopenia
Frailty is emerging as a new and more specific predictor of morbidity and mortality
in patients with CVD [96] (acute myocardial infarction, heart failure, heart valve disease).
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On the other hand, frailty seems to be a more accurate perioperative risk score than those
currently used in patients underwent cardiac surgery and transcatheter aortic valve replace-
ment. Recently, Graham et al. [97] analyzed the prognostic significance of frailty measure by
the EFS in patients ≥65 years of age admitted to the hospital with acute coronary syndrome.
Patients with higher EFS scores (i.e., more frailty) were older, had greater comorbidity, and
were less suitable for revascularization. An EFS ≥7 was related to a longer duration of hos-
pitalization and mortality compared with those with an EFS score ≤3. In a cohort of older
patients hospitalized with non-ST-elevation myocardial infarction, Ekerstand et al. [98]
assessed that frailty, quantified by the clinical frailty score (CFS), was an independent
predictor of major adverse events (death, reinfarction, revascularization, major bleeding,
stroke or renal replacement therapy, rehospitalization) at 1 month. In a follow up, Sanchis
et al. [99] analyzed the relationship between clinical factors and laboratory parameters
(i.e., inflammation, coagulation activation, hormonal dysregulation, nutritional status, kid-
ney and cardiac function), frailty and a composite of death/myocardial infarction among
survivors of ACS at the time of hospital discharge. Four clinical variables (age ≥75 years, fe-
male sex, ischemic heart disease, heart failure) and three laboratory variables (hemoglobin
≤125 g/L, vitamin D level ≤9 mg/dL, cystatin Clevel ≥1.2 mg/dL) had a predictor power
similar to that of the Fried criteria for the composite outcome. Frailty might also have
important prognostic implications also in patients with heart failure (HF). About 18–54%
of patients with heart failure (HF) are frail [100]. A baseline frail state was found to in-
dependently predict incident HF [101]. Frailty was associated with higher likelihood of
hospitalization for HF decompensation and 1-year mortality [102]. On the other hand, the
presence of frailty at the time of left ventricular assist device implantation in patients with
end stage-HF was shown to be associated with longer recovery time, a risk for rehospital-
ization and mortality [103]. Frailty has been increasingly recognized to have significance
in predicting the risk of perioperative complications, resource use, and outcomes after
cardiac surgery. In a lot of studies, frailty seems to improve and outperform conventional
perioperative risk scores for predicting adverse outcomes [104]. A recent systematic review
showed a significant association with postoperative mortality and major cardiac and cere-
brovascular events (MACCE) and frailty [105]. In addition, Sudermann et al. [35] assessed
a moderate correlation of the frailty with the EuroSCORE and the Society of Thoracic
Surgeons (STS) scores to predict mortality in patients aged ≥74 years who were referred to
cardiac surgery. In conditions where new scale is used (SHARE-FI scale), frailty seems to be
better than the EuroSCORE II in predicting 1-year mortality. The role of frailty evaluation
in predicting morbidity and mortality after cardiac surgery has been studied in different
types of surgical procedures: aortic valve replacement [106], mitral valve surgery [107],
coronary artery bypass surgery [108]. Finally, the most important application of the frailty
evaluation in terms of prognostic factor is the transcatheter aortic valve replacement (TAVR)
field [109]. In fact, patients undergoing TAVR are generally older, have multimorbidities
and are frail. Stortecky et al. evaluated the association between preoperative multidimen-
sional geriatric assessment (MGA) and 30-day and 1-year risk of MACCE and mortality
among 100 patients undergoing TAVR. Nearly all domains of the MGA evaluated showed
association with MACCE and death [110].
9. Dietary Intake to Prevent Sarcopenia in Patients Undergoing Cardiac Surgery
The cardiac operation is a moment of stress for ill patients. Metabolic demands and
muscle breakdown are accelerated by bedrest and poor oral intake causing an important
loss of muscle mass. This is particularly deleterious for frail older patients, who have lower
reserves of muscle mass and strength [111]. Frailty increases the age-related changes in
protein and muscle metabolism by increasing the rate of protein catabolism and decreas-
ing the response to anabolic factors. A correct protein intake is necessary in particular
in ill patients [112] (Table 1). The American Society for Parenteral and Enteral Nutri-
tion (ASPEN) advised a protein intake of 2.0 g per kilogram of body weight per day
(g/kg/d) [112]. Instead the European Society for Parenteral and Enteral Nutrition (ESPEN)
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recommends 1.5 g/kg/d [113]. On the other hand, these guidelines recommended aggres-
sive postoperative nutritional support, including early enteral nutrition when necessary
to meet the postoperative caloric and protein needs. In fact, in the 6 weeks after cardiac
surgery, older adults lose on average 5% of their body mass, and this increased the risk of
readmission in the hospital [114]. A study of patients admitted to the surgical intensive
care unit showed that those with a postoperative protein deficit were less likely to be
discharged home [115]. A multinational study revealed that consuming close to the recom-
mended protein intake was associated with 60-day survival and ventilator free days [116].
A prospective interventional study demonstrated that aggressive protein supplementation
was associated with a 66% reduction in infectious complications in the surgical intensive
care unit [117]. A retrospective study of 1007 postsurgical patients at eight hospitals found
that those with sufficient protein intake, defined as >60% of the recommended protein
intake, had decreased length of stay and hospital costs [118]. The Nutrition Care in Cana-
dian Hospitals (NCCH) study showed that surgical patients who ate less than half of the
provided food had signs of malnutrition and increased length of stay [119]. To improve
the nutrition of patient candidates for surgery, one of the core components of the ERAS
program is a recommendation to liberally prescribe oral nutritional supplements in the pre-
and postoperative periods [120]. Exercise plays a key role in the prevention and treatment
of sarcopenia and today it is the most effective approach. Through the stimulus given
by physical activity, numerous pathways are activated at the muscle level that converge
towards anabolic pathways, with positive consequences on trophism and muscle quality.
In particular, it is the moderate intensity resistance exercises that produce the most results.
Intense exercise does not bring further benefits, if not actually harmful [121].
Table 1. Dietary protein intake and sarcopenia.




2010 until April 2015
The first group, containing
eight articles, discussed
protein or amino acid
supplementation alone on
sarcopenia. The second group,
containing six articles,
discussed exercise alone on
sarcopenia. The last group,
containing six articles,
discussed both protein or
amino acid supplementation
and exercise on sarcopenia
Naseeb MA et al.
[122]
Protein intakes should exceed
the current recommended
dietary allowance RDA








Healthy older people for older
people who are malnourished
or at risk of malnutrition
because they have acute or
chronic illness.
Older adults above 65 years
Deutz NE et al.
[121]
Higher protein intakes in older
adults in relation to the current
protein
RDA: a 25–50% increase for
healthy individuals, a 50–90%
increase those suffering from
acute or chronic disease, and
greater than 50% increase above
the RDA for those experiencing








Data from 11,680 adults were
categorized into 51–60
years (n = 4016), 61–70 years
(n = 3854), and 71 years and
older (n = 3810) for analysis
Krok-Schoen JL et al.
[123]





the current RDA or
twice the RDA (2RDA)
affects skeletal muscle
mass and physical
function in elderly men
Before treatment and
after 10 wk of
intervention
29 men aged > 70 y
(mean ± SD) body mass index
(in kg/m2): 28.3 ± 4.2
Mitchell CJ et al.
[124]
Increasing protein intake to
twice RDA (1.6 g/kg per day)
resulted in significant gains in
lean tissue mass in healthy
older men
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Table 1. Cont.






/ Elderly population of theUnited State Baum JI et al. [125]
The consumption of dietary
protein consistent with the
upper end of the AMDRs (as
much as 30–35% of total caloric
intake) may prove to be
beneficial, although practical
limitations may make this level
of dietary protein intake difficult
The consumption of high-quality
proteins that are easily digestible
and contain a high proportion of
EAAs lessens the urgency of
consuming diets with an










inclusion criteria, five records
were on short-term and three
records on long-term appetite
Mollahosseini M
et al. [126]
Increasing daily protein intake to
twice the RDA translates to an
80 kg older adult consuming
about 130 protein daily. Given
that protein increases satiety in a
dose-dependent manner
Review Seniors over 50 with reducedprotein intake
Paddon-Jones D
et al. [127]
Results from muscle protein
anabolism, appetite regulation
and satiety research support the
contention that meeting a
protein threshold
(approximately 30 g/meal)
represents a promising strategy
for middle-aged and older
adults concerned with










amount and type of key







men and women, 65 years and
older (n = 330)
Cramer JT et al.
[128]
The recommendation to increase
protein intake while
simultaneously maintaining, and
in many cases increasing,
energy intake can present a
protein paradox. Dietary
supplementation strategies to
increase protein intake may
unintentionally result in partial
energy redistribution, which
may negatively affect both









Eight healthy male volunteers
with mean (± E) age 27 ± 2 yr,
body weight 84 ± 3 kg, height
181 ± 3 cm, and maximal leg
strength 430± 13 kg
Moberg M et al.
[129]
The capacity of resistance
exercise to sensitize muscle to
the anabolic potential of dietary
protein is primarily achieved






were separated by a
minimum of 7 days
Seven (n = 7) younger
(18–45 years; four males, three
females) and seven (n = 7)
older (60–80 years; four males,
three females) volunteers
Lees MJ et al. [130]
The ingestion of a novel,
gel-based, leucine-enriched EAA
supplement results in substantial
aminoacidemia and anabolic
signaling in younger and older
individuals. This formulation
can augment dietary protein
consumption, intracellular
anabolic signaling, and
aminoacidemia in older adults
without deleterious effects on
appetite and subsequent
energy intake
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Table 1. Cont.
Study Type Duration of the Study Material and Methods References Main Findings
A systematic review of
interventional evidence
was performed through
the use of a
random-effects
meta-analysis model





680 subjects Cermak NM et al.[131]
Gains in lean tissue mass were of
greater magnitude in both
younger and older adults when
combining resistance training
with protein supplementation vs.
resistance training alone.
Increases in type II muscle fiber

















during resistance training when
habitual dietary protein intakes
were, on average, below 1.6 g/kg
body mass per day in younger
adults. However, the impact of
protein supplementation on






in elderly 80 years old
or older
/
Elderly cohorts including very
old participants aged 80 years
and older
Franzke B et al.
[133]
The amino acid composition of a
given protein source can
influence the extent and
amplitude of postprandiam









/ Persons aged > 80 y sarcopenic Traylor DA et al.[134]
The leucine content of a given
protein source is particularly
important in attenuating
declines in a muscle mass when
consumed alongside other
essential amino acid EAA
Clinical trials anabolic
response to essential
amino acid plus whey
protein composition is
greater than whey
protein alone in young
healthy adults
/
16 healthy male and females.
Characteristics: age, body
weight, body mass index, lean
body mass, fat mass
Park S et al. [135]
Provision of ample dietary EAA
and leucine are necessary to
support a skeletal muscle
anabolic response in older adults.
Nutritional supplementation
with EAA and leucine alongside
meals containing suboptimal
protein content (i.e., breakfast
and lunch) could assist older










(n = 8; 21 ± 2 y old
(mean ± SEM); body
mass index (in kg/m2):
22.9 ± 0.9) began in
January 2008
Eight postabsorptive healthy
men (≈21 y of age) were




biopsies for determination of
muscle protein synthesis MPS
and anabolic signaling
Atherton PJ et al.
[136]
When skeletal muscle is
refractory to the anabolic effects
of leucine during the
postprandial ‘muscle-full’
period, it would be prudent that
protein-based snacks or
supplements are administered
between meals when additional
nutritional supplementation is










older males (n = 16,
70.3 ± 2.6 years, BMI 25.5 ± 1.8
(mean ± SD) were recruited by
mail and local advertising
Mitchell WK et al.
[137]
Supplements may be most likely
to be effective when taken in
between meals, perhaps in the
form of low dose EAA mixtures,
rather than leucine alone; the
efficacy of which may be limited
in the absence of exogenous
EAA to promote whole body
and skeletal muscle net balance
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10. Conclusions
Frailty is the major expression of a decreased resistance to stressors, and consequently
an increased vulnerability to additional diseases in elderly people. Sarcopenia can be
considered a biological substrate of physical frailty. The vascular aging related to frail
phenotype reflects the high susceptibility for cardiovascular diseases and negative postop-
erative outcomes after cardiac surgery. For this reason, a frail phenotype is a risk factor
of mortality and morbidity for several diseases. A lot of biomarkers have been identified
as expression of the crosstalk between frailty and cardiovascular diseases in molecular
mechanisms level.
Malnutrition plays a key role in the pathogenesis of sarcopenia and frailty. Malnutri-
tion is defined as an imbalance condition of protein or other nutrient imbalance, responsible
for negative effects on body composition, physical function and clinical outcome. An opti-
mal nutrition status and protein intake, as well as a moderate intensity resistance exercise
are the key points. Accordingly, in the future the role of a specialized team-workers will be
very important in the management of cardiac surgery patients. Cardiac surgeons, cardi-
ologists, geriatricians, physiatrists, and dieticians should work in a complementary way
in order to better prepare patients undergoing cardiac surgery and reduce postoperative
mortality and morbidity.
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